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Abstract
Fundamental aspects of human behavior operate outside of conscious awareness. Yet, theories of conditioned responses in
humans, such as placebo and nocebo effects on pain, have a strong emphasis on conscious recognition of contextual cues that
trigger the response. Here, we investigated the neural pathways involved in nonconscious activation of conditioned pain
responses, using functional magnetic resonance imaging in healthy participants. Nonconscious compared with conscious
activation of conditioned placebo analgesiawas associatedwith increased activation of the orbitofrontal cortex, a structurewith
direct connections to affective brain regions and basic reward processing. During nonconscious nocebo, there was increased
activation of the thalamus, amygdala, and hippocampus. In contrast to previous assumptions about conditioning in humans,
our results show that conditioned pain responses can be elicited independently of conscious awareness and our results suggest
a hierarchical activation of neural pathways for nonconscious and conscious conditioned responses. Demonstrating that the
human brain has a nonconscious mechanism for responding to conditioned cues has major implications for the role of
associative learning in behavioral medicine and psychiatry. Our results may also open up for novel approaches to translational
animal-to-human research since human consciousness and animal cognition is an inherent paradox in all behavioral science.
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Introduction
Conditioning is known to play an important role in the formation
of treatment expectations and placebo responses (Kirsch et al.
2004). In the case of placebo analgesia, the association between
a treatment cue (e.g.,morphine shot) and the following pain relief
creates predictive knowledge that modulates future pain re-
sponses to the same cue, even if the shot contains saline (Buchel
et al. 2014). Until recently, theories concerning placebo and
nocebo (negative placebo) mechanisms had a strong emphasis
on conscious expectations (Kirsch et al. 2004), suggesting that
higher-order areas of the brain process the predictive cues asso-
ciated with pain relief (Wager et al. 2004; Petrovic et al. 2010).
However, neuroimaging studies suggest that the human brain
can process sensory information before it reaches conscious
awareness (Morris et al. 1998; Whalen et al. 1998; Pessiglione
et al. 2007, 2008), and thus, predictive cues may be recognized
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subliminally andmediate nonconscious effects on human cogni-
tion and behavior.
The central nervous system can modulate incoming sensory
information at different levels of adaptation, including automatic
responses with little ﬂexibility, and highly ﬂexible processes
modiﬁed by associated contexts and consequences (Mesulam
1998). According to this hierarchical theory, reward cues may be
processed unconsciously through direct activation ofmesolimbic
reward areas (Pessiglione et al. 2007, 2008). Similarly, fearful stim-
uli can be conveyed via direct thalamic projections to the amyg-
dala or indirect, slower, cortical pathways (Mesulam 1998;
LeDoux 2000). As placebo analgesia involves reward-related
brain processes (Schweinhardt et al. 2009; Scott et al. 2009) and
nocebo involves fear-related mechanisms (Benedetti et al.
2006), we hypothesized that placebo and nocebo pain responses
could be triggered nonconsciously through rapid pathways for re-
ward and fear processing. In a recent behavioral study, we de-
monstrated the feasibility of activating conditioned placebo and
nocebo pain responses via nonconsciously presented visual cues
(Jensen et al. 2012). Here, we investigated the neural circuitry in-
volved innonconscious activation of conditioned pain responses.
We used functional neuroimaging during a within-subject para-
digm of conscious and nonconscious activation of conditioned
placebo and nocebo responses. We hypothesized that brain re-
gions associated with direct and rapid processing of reward,
like the nucleus accumbens (Pessiglione et al. 2008) and orbito-
frontal cortex (OFC) (Thorpe et al. 1983; Zhang et al. 1997),
would be more activated during nonconsciously compared with
consciously activated “placebo.” We also hypothesized that sub-
cortical regions with direct processing of threat and pain signals,
such as the amygdala (Whalen et al. 1998; Öhman et al. 2007),
hippocampus (Ploghaus et al. 2001; Mobbs et al. 2009), and thal-
amus (Wager et al. 2004), would be more active during noncon-
sciously compared with consciously activated “nocebo.”
Materials and Methods
Participants
Participants (n = 24, 10 women; mean age 25 ± 5) were right-
handed and had no previous experience with fast image expo-
sures or masking experiments. Participants were considered for
the study if they had no chronic health issues, no psychiatric
symptoms or ongoing medications (except for hormonal contra-
ception). Participants were not allowed to use any analgesic
drugs within 48 h of the study visit. All participants were
screened for magnetic resonance imaging (MRI) eligibility and
were recruited through posted ﬂyers at several different univer-
sities and at information boards in residential buildings. Partici-
pants were reimbursed for parking and also received a small
monetary compensation for their participation (<$100).
Equipment
Measurements of brain activity were performed using a 3 Tesla
Siemens MRI System equipped for Echo Planar Imaging (EPI).
Thermal pain stimuli were delivered using the Pathway system
from Medoc (www.medoc-web.com), with a 30-mm ATS ther-
mode. Inside the scanner, a Sharp XG projector with 1024 × 768
resolution was used for visual presentations, connected to a
Lenovo desktop computer. The experiment was programed in
Presentation 13.0 (Neurobehavioral Systems, www.neurobs.com).
The refresh rate was set to 85 Hz, and the masked stimulus pre-
sentations were synchronized with the refresh rate to elicit very
fast exposures that prevented visual recognition (12 ms). The
images used in the current experiment were taken from The
Karolinska Directed Emotional Faces set (www.emotionlab.se/
resources/kdef ); a set of images speciﬁcally developed for use
in perception, attention, emotion, memory, and masking ex-
periments. The whole set consists of 70 individuals (35 males,
35 females), mean age 25 years (range 20–30) with 7 different
facial expressions per individual. The images used in the present
experiment represented men in neutral expressions, that is, no
emotional valence. In total, 12 different neutral male faces were
used for the purpose of this study.
Procedure
Participants were screened for inclusion and exclusion criteria
over the telephone and then scheduled for an experiment. Parti-
cipants were informed that the study investigated “the inﬂuence
of implicit and explicit learning on pain perception,” but the full
purpose of the study was not revealed until the experiment was
over, and all participants were debriefed. All participants gave
written informed consent, and the studywas approved by the In-
stitutional Review Board at the Massachusetts General Hospital,
Boston, MA.
After giving informed consent, the Medoc ATS heat thermode
was placed on the participants’ volar forearm. Ascending tem-
peratures were applied in order to ﬁnd a calibrated temperature
that would represent each participants “high pain” rating, ap-
proximately in the range of ∼15 on a 0–20 Numeric Response
Scale (NRS) ranging from “no pain” to “worst imaginable pain,”
and a “low pain” rating of ∼5 NRS. The difference between the
chosen high and low pain temperature was ﬁxed to 3°C for all
subjects, for example, high pain/low pain could be represented
by 49°/46°C in 1 individual and 47°/44°C in another. When the
calibration of pain temperatures was complete, participants
were placed in the scanner. The pain stimulator was placed on
the left arm, and participants had a response-device in their
right hand that would allow for pain ratings while in the scanner.
Participants were given the following instruction before the con-
ditioning run: “You are about to see some pictures on the screen.
Each picture is pairedwith a pain stimulus on your arm. Your task
is to focus on the screen at all times and after each picture I would
like you to rate how much pain you felt on your arm, using the
same 0–20 scale that you used during the calibration.” In order
to ensure that subjectsmaintained high attention, the condition-
ing sequencewas divided in 2 blocks of ∼10 min each. In total, 50
stimuli were presented during the conditioning sequence; 25 for
the high pain face and 25 for the low pain face. Between trials,
there was a jittered inter stimulus interval (ITI) between 8 and
12 s. After the conditioning cue (duration 100 ms), the painful
stimuluswas applied for 4 s, followedbya 2 to 6-s jitteredwait be-
fore the pain rating of 8 s. Depending on the individual tempera-
ture used for each participant, the total time for ramp up and
down of the heat varied between 2.2 and 3.5 s, with higher tem-
perature corresponding to longer ramp time. For fMRI data ana-
lyses, we modeled the pain duration at 6 s to include the ramp
up and down of heat and ensure that the disappearance of the
heat would not overlap with the rating task.
Immediately after the conditioning runs, subjects were given
the following instruction “You are about to see the same pictures
on the screen again and each picture will be paired with a pain
stimulus on your arm, just like before. The only difference is
that this time therewill also be pictures of new guys, that you ha-
ven’t been exposed to before. Your task is to focus on the screen
at all times and after each picture I would like you to rate how
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much pain you felt on your armusing the 0–20 scale. The pictures
will sometimes be shown to you much faster than before, and
you might not be able to recognize them. This is normal and
something that we programmed on purpose. Your only task is
to focus on the screen at all times and rate the pain on your
arm, even if you can’t see the pictures.” The test sequence con-
sisted of 60 stimuli: 20 for the high pain condition, 20 for the
low pain condition, and 20 for the neutral condition. Half of
these stimuli were conscious, and half were unconsciously pre-
sented. The test sequence was divided in 3 10-min runs.
To verify that the masked stimuli would be truly non-recog-
nizable, we performed a forced-choice recognition test immedi-
ately after the test sequence. The instructions were as follows:
“You are about to see some pictures on the screen again and I
would like you to answer if you have seen this face before during
the experiment. You can only say ‘yes’ or ‘no’. The pictureswill be
exposed to you very quickly so youmight not be able to tell if you
saw it before or not. In any case, you have to guess ‘yes’ or ‘no’ for
each exposure.”The recognition test included 12 exposures of the
previously used high, low, and control faces and 12 exposures of
new faces. Participants were asked to indicate whether the face
had been shown before, or not. Our previous studies have veriﬁed
that the nonconscious image exposures used in this experiment
are indeed non-recognizable to the participants (Jensen et al.
2012) and the forced-choice task is commonly used experimental
method for assessing participants’ ability to recognize masked
visual stimuli (Pessiglione et al. 2007).
MRI Parameters
Two functional MRI runs were performed during conditioning,
and 3 runs were performed during the test sequence. Thirty
axial interleaved slices (4 mm thick with 1 mm skip) parallel to
the anterior and posterior commissure covering the whole
brain were acquired with TR = 2000 ms, TE = 40 ms, ﬂip angle =
90°, and a 3.13 × 3.13-mm in-plane spatial resolution. The num-
ber of time points was 293 for each of the functional runs. In add-
ition to the functional MRI scans, participants were also scanned
with a high-resolution MPRAGE sequence for anatomical refer-
ence. During the entire scan, cushions and earplugs were used
to reduce head movement and dampen scanner noise.
Statistical Analyses
All statistical analyses of behavioral datawere performed in SPSS
Version 20.0. A statistical signiﬁcance threshold of P < 0.05 was
considered, and all tests were two-tailed. The difference in pain
ratings between the “low cue,” “high cue,” and “control cue” trials
was analyzed using repeated-measures ANOVA. If the overall
ANOVA was signiﬁcant, pairwise comparisons between the dif-
ferent conditions were performed with t-tests. Correlation ana-
lyses were performed using Pearson’s r.
Preprocessing and analyses of imaging data were performed
using the Statistical Parametric Mapping 8 (SPM8) software
(SPM8, Wellcome Trust Centre for Neuroimaging) and Matlab
7.4 (Mathworks). All functional brain volumes were realigned
to the ﬁrst volume, spatially normalized to a standard EPI tem-
plate, and ﬁnally smoothed using an 8-mm full-width at half-
maximum isotropic Gaussian kernel. High-pass ﬁltering of fMRI
data (cutoff: 128 s) and correction for temporal autocorrelations
using AR(1) were also done. The univariate data analysis was per-
formed using the general linear model. The individual design
matrix for each participant (ﬁrst-level matrix) included the fol-
lowing regressors for the conditioning run: high cue, low cue,
high pain, low pain, high rating, and low rating. The matrix also
included the following test-sequence regressors twice, 1 for con-
scious and 1 for nonconscious trials: high cue, low cue, control
cue, high pain, low pain, control pain, high rating, low rating,
and control rating. A ﬁle containing the movement parameters
for each individual (3 translation and 3 rotation axes) was ob-
tained from the realignment step and saved for inclusion in the
model. Regression coefﬁcients for all regressors were estimated
using least squares within SPM8. Speciﬁc effects were tested by
creating contrasts of the parameter estimates, resulting in a
t-statistic for each voxel. After the individual ﬁrst-level estima-
tions, a second-level analysis was performed using a within-
subject ANOVA. For the main effect of high- minus low-pain
stimulation during conditioning, an initial statistical threshold
of voxel-wise P < 0.01 was used for all analyses, and all reported
clusters were family-wise error corrected over the entire brain.
For the evaluation of conscious and nonconscious placebo/no-
cebo effects, we applied a region of interest (ROI) approach. An
initial threshold of P < 0.01 was used, and corrections were
based on previous studies on placebo, nocebo, or nonconscious
processing. In line with previous placebo neuroimaging studies,
the rostral anterior cingulate cortex (ACC) andOFCwere corrected
using spheres of 12 mm radius and the nucleus accumbens, pu-
tamen, amygdala, hippocampus, and thalamus were corrected
using spheres of 6 mm radius (Eippert et al. 2009). Extraction of
parameter estimates for a speciﬁc ROI was performed by extract-
ing a 3-mm sphere around the peak voxel.
Results
In concert with our previous report (Jensen et al. 2012), both con-
scious and nonconscious presentation of the conditioned cues
led to signiﬁcant placebo and nocebo responses. A repeated-
measures ANOVA showed a main effect for cue type (high/low/
control), F2,40 = 53.28, P < 0.001 and no signiﬁcant main effect for
exposure type (conscious/nonconscious) F1,40 = 1.45, P = 0.24. As
illustrated in Figure 1, the exposure by cue interaction did not
reach signiﬁcance, F2,40 = 3.07, P = 0.06, but pointed toward a
trend of larger “low cue” responses during conscious compared
with nonconscious trials. Post hoc comparisons indicated signiﬁ-
cant placebo and nocebo effects for both conscious and noncon-
scious stimuli (P < 0.001).
An initial validation of brain activations in response to pain
during the conditioning sequence revealed a comprehensive re-
presentation of pain processing regions [high pain > lowpain], in-
cluding the ACC, thalamus, and bilateral insula; see Table 1.
Themain effect of “placebo” during the test sequence, deﬁned
as the neural activation during “low cue versus “control cue”
trials, irrelevant of exposure type, revealed increased activation
in the rostral ACC (rACC) (Montreal Neurological Institute coordi-
nates [9, 26, −8]); a commonly reported region in placebo anal-
gesia (Bingel et al. 2006; Kong et al. 2006). A comparison of pain
responses during nonconscious versus conscious placebo trials
revealed higher activation in the OFC during nonconscious trials
([36, 29, −2]). During clearly conscious placebo trials, there was a
trend toward higher activation in the visual cortex; however, it
did not reach signiﬁcance (P = 0.07).
Themain effect of “nocebo” during the test sequence, deﬁned
as the pain response during “high cue” versus “control cue” trials,
irrelevant of exposure type, revealed increased activation in sev-
eral regions involved innociceptive processing, for example, ACC,
bilateral insula, thalamus, and brainstem. Awithin-subject com-
parison of nocebo responses during nonconscious versus
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conscious trials revealed higher activation of the brainstem, thal-
amus, amygdala, and hippocampus (Table 1; Figure 2).
To further investigate the fMRI signal change in the amygdala
during nonconscious nocebo trials, the signal in right and left
amygdala was extracted and correlated with the reported pain
ratings. There was a positive correlation between pain ratings
during nonconscious nocebo trials and activation of the right
amygdala (r = 0.52, P < 0.05) but not for the left amygdala (r = 0.32,
P = 0.10) (Figures 3 and 4).
To elucidate the link between the predictive value of the aver-
sive high pain signal, and subsequent neural responses to non-
conscious nocebo cues, a correlation analysis between high
pain reports during conditioning and amygdala activity during
nonconscious nocebo trials was performed. Results demonstrate
that high pain ratings during conditioning correlated with high
activation of the amygdala during nonconscious trials, both for
the right amygdala (r = 0.49, P < 0.05) and the left amygdala (r = 0.48,
P < 0.05) but not for conscious nocebo trials.
Discussion
The present study demonstrates a neural mechanism for non-
conscious activation of conditioned placebo/nocebo responses,
including cortical as well as subcortical brain regions. During
nonconsciously activated placebo analgesia, we found increased
activation in the OFC, compared with consciously presented
trials. The OFC is a phylogenetically old part of the prefrontal cor-
tex (Thorpe et al. 1983) and has been widely described in studies
of reward processing (Kringelbach 2005; O’Doherty and Dolan
2006) but also in placebo analgesia (Wager et al. 2004; Petrovic
et al. 2010). Emerging evidence suggest that placebo analgesia
share neural substrates with reward processing (Schweinhardt
et al. 2009; Scott et al. 2009), which might suggest that noncon-
scious placebo activation of the OFC represents a reward-related
signal rather than cognitive inhibition of nociception (Leknes
et al. 2011). A recent study on monetary reinforcements demon-
strated that we can learn to associate rewards with contextual
cues, even without conscious processing (Pessiglione et al.
2008). Hence, it is possible that conscious expectation of pain
relief, often reﬂected in the lateral prefrontal cortex, is not neces-
sary to activate the more archaic OFC in response to conditioned
placebo cues. Previous placebo studies, using consciously per-
ceived cues, often report a mix of reward-related regions and in-
hibitory regions in the lateral prefrontal cortex (Kong et al. 2006,
2013), suggesting that there is considerable overlap between the
brain regions recruited during conscious and nonconscious pla-
cebo. Results from the animal literature, however, support our
ﬁnding by reports showing that stimulation of the OFC can acti-
vate endogenous analgesia through neural projections inde-
pendently from conscious evaluation (Zhang et al. 1997). The
OFC is not only activated by reward stimuli per se, and studies
(Rolls 2000; O’Doherty et al. 2002) have demonstrated signiﬁcant
Figure 1. Experimental procedure. The conditioning procedure (A) included clearly recognizable images of 2 male faces (experimental cues) presented on a computer
screen. Each face cue was consistently paired with either a high or low heat pain stimulus on the volar forearm. After conditioning, a test sequence was performed
(B) in which the high cue, low cue, and a neutral control cue were paired with identical moderate heat stimuli. During the test sequence, 50% of the cue exposures
were exposed long enough for all subjects to clearly recognize them (100 ms), and 50% of the face cues were exposed for only 12 ms and then followed by a mask to
prevent conscious recognition (backward-masking). (C) A detailed description of the trial timing during fMRI scans. The ITI lasted between 8 and 12 s.
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OFC activation during anticipation as well as receipt of a reward.
This is similar to placebo responses since they may be seen as
(conscious or nonconscious) representations of expected relief.
Also, studies suggest that reward processing in the OFC repre-
sents prediction of error responses thatmediate learning through
updating expected/actual rewards (O’Doherty 2007). Along these
lines, it is possible that the OFC in our studywasmore involved in
coding the mismatch between the expected and perceived pain-
ful stimulus during nonconscious, compared with conscious
trials. We suggest that the brain’s internal representation of the
painful stimulus can be adjusted and accounted for through dif-
ferent circuitry, with more or less ﬂexibility, leading to the differ-
ential neural representations of placebo analgesia seen in the
present study.
Nonconscious nocebo responses were associated with in-
creased activations in fear-related subcortical structures of the
brain, possibly reﬂecting processing of a perceived threat, since
participants learn to associate the high cuewith a highly aversive
Table 1 Results from fMRI statistical analyses
Pain main effect [high pain > low pain] MNI x MNI y MNI z Cluster size (voxels) Z-score FWE P-value
Middle/posterior insula 36 5 7 473 4.08 P < 0.05
Posterior insula −33 −16 16 590 3.60 P < 0.05
ACC 0 17 34 592 3.41 P < 0.05
Thalamus 0 −16 7 67 3.30 P < 0.05
Placebo main effect
R. rostral ACC 9 26 −8 20 3.07 P < 0.05
Placebo [nonconscious > conscious]
R. orbitofrontal cortex 36 29 −2 116 3.12 P < 0.05
Placebo [conscious > nonconscious]
L. cuneus visual cortex −3 −91 28 30 3.25 P = 0.07
Nocebo main effect
L. cingulate cortex 0 −13 31 848 3.53 P < 0.05
L. posterior insula −42 −4 4 563 3.26 P < 0.05
R. hippocampus/temporal pole 42 2 −14 146 3.05 P < 0.05
R. posterior insula 39 −1 −2 24 2.76 P < 0.05
L. thalamus −6 −19 −5 56 2.90 P < 0.05
Nocebo [nonconscious > conscious]
R. brainstem 9 −16 −5 1768 3.07 P < 0.002
R. thalamus 6 −1 10 28 3.00 P < 0.05
R. amygdala 30 −4 −14 203 3.10 P < 0.05
R. hippocampus 33 −10 −14 203 3.10 P < 0.05
Nocebo [conscious > nonconscious]
None
Note: The painmain effect refers to the brain activations in response to thermal pain during the conditioning run [high pain > low pain]. Brain activations during placebo
and nocebo trials arewithin-subject comparisons. Coordinates (x, y, z) correspond to the anatomical space as deﬁned in theMNI standard brain atlas. The initial statistical
threshold was P < 0.01, and all reported clusters are FWE-corrected at the cluster level.
Figure 2. Pain ratings during conscious andnonconscious placebo andnocebo trials. Identicalmoderate temperatureswerepairedwith a conditioned “high pain cue,” “low
pain cue,” or “control cue” to test how predictive cues changed participants’ pain perception. Participants rated pain intensity on a 0–20 Numerical Response Scale (NRS).
Left panel: representation of the within-subject pain ratings during the test sequence that followed the initial conditioning sequence. Bars represent the average pain
rating in response to identical moderate temperatures. Error bars represent 2 intrasubject standard errors. Top asterisks (*) represent overall signiﬁcance for “cue type”
and lower asterisks represent signiﬁcant pairwise comparisons between the cues. Right panel: illustration of the interaction of “cue type” (high, low, control) by “exposure
type” (conscious, nonconscious), based on a within-subject design.
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outcome. Previous neuroimaging studies have demonstrated
how fear responses can occur without conscious perception of
the fear cue (Phelps 2005), with special emphasis on the role of
the amygdala and adjacent subcortical structures known to fa-
cilitate rapid recognition of threat (Morris et al. 1998; Carlsson
et al. 2004).We found increased activity in the right hippocampus
and amygdala during nonconscious nocebo, compared with con-
scious nocebo trials, furthering the role of the amygdala and
hippocampus in conditioned responses of an aversive domain
that is not necessarily fear-related, but related to pain (Kong
et al. 2008; Bingel et al. 2011). Moreover, we found that higher ac-
tivation of the amygdala during nonconscious nocebo trials cor-
relatedwith the pain ratings during these trials. The link between
the deliberate choice of a pain rating and the activation of the
right amygdala during nonconscious nocebo trials supports pre-
vious suggestions of ways that unconscious motivation may af-
fect our decisions and goal pursuits (Dijksterhuis et al. 2005;
Custers and Aarts 2010).
Our ﬁndings of differential brain activation with noncon-
scious cues, compared with conscious cues, add to previous
evidence of 2 processes by which placebo and nocebo responses
are conveyed. Amanzio and Benedetti (1999) reported that con-
scious expectations of pain relief were associated with placebo
effects that were naloxone reversible but that placebo effects in-
duced by conditioning with a non-steroidal anti-inﬂammatory
drug, without conscious expectations of an analgesic response,
were not naloxone reversible. In another study from the same la-
boratory (Benedetti et al. 2003), verbally induced expectations
completely reversed the effects of conditioning on conscious pla-
cebo responses (pain and motor movements), but not on non-
conscious responses (hormonal secretion). Our study is clearly
related to these previous studies, and in addition to adding neu-
roimaging, we also adopted amodiﬁed theoretical approach. The
previous 2 studies compared conscious versus nonconscious
bodily functions (i.e., pain ratings versus hormonal secretion), al-
ways presenting the treatment cues in plain sight (e.g., intraven-
ous injectionwith a syringe, which the subjects are clearly seeing
and feeling). The present study used conscious versus non-
conscious conditioned cues, which means that the subject was
either aware or not aware of the treatment cue. In its most
Figure 4. Amygdala activation during nocebo and correlation to pain ratings. Left panel: coronal representation of the increased activation in the right amygdala during
nonconscious nocebo. The initial statistical threshold was P < 0.01, family-wise corrected for ROI. Right panel: a correlation analysis between extracted amygdala
parameter estimates during nonconscious nocebo trials and the associated nocebo rating (r = 0.60, P < 0.005).
Figure 3. Neural correlates to nonconscious placebo and nocebo responses. Left panel: the nonconscious placebo condition, compared with conscious placebo, was
associated with increased activity in the OFC, as illustrated by the circle. Middle and right panel: the nonconscious nocebo condition, compared with conscious
nocebo, was associated with increased activity in the amygdala, hippocampus, and thalamus. The initial statistical threshold was P < 0.01, family-wise corrected for ROI.
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simple form, our experiment would be as if Pavlov would ring his
bell (or more correctly he might have used tones or buzzers) at a
consciously undetectable frequency (conditioned stimulus) to
test the effects of conditioned pain responses. Nonetheless, all
3 studies, taken together, support the conclusion that “condition-
ing procedures and other sources of information sometimes
shape conscious expectancies and that these expectanciesmedi-
ate some placebo effects; however, in other cases conditioning
procedures appear to shape placebo effects that are notmediated
by conscious cognition” (Stewart-Williams and Podd 2004).
The behavioral data revealed signiﬁcant placebo and nocebo
effects in response to both conscious and nonconscious cues;
however, an interaction analysis revealed a trend toward larger
conscious than nonconscious placebo responses. This difference
is most likely due to enhanced analgesia expectancies during
conscious trials. This interpretation is consistent with previous
studies, in which it has been shown that placebo analgesia in-
duced by classical conditioning and verbal suggestions together
is of greater magnitude than placebo analgesia induced by verbal
suggestions alone (Amanzio and Benedetti 1999; Benedetti et al.
2003; Colloca et al. 2008; Colloca and Benedetti 2009) and that the
effect of a conditioned stimulus is also mediated by expectancy
(Montgomery and Kirsch 1997; Watson et al. 2006, 2007; Kirsch
et al. 2014).
The present study has several limitations. First of all, the pla-
cebo andnocebo effectswere obtained in an experimental setting
and cannot be directly translated to clinical situations. Also, the
differences in pain ratings were statistically signiﬁcant butmight
not represent large enough effects from a clinical perspective. In-
stead, our experiment was optimized for probing differences in
neural processing of nonconscious versus conscious treatment
cues, using well-deﬁned a priori hypotheses based on previous
neuroimaging studies. The statistical effects were modest but
similar to the effects observed in other placebo neuroimaging
studies with similar sample size. Furthermore, the correlation
analyses of extracted amygdala values and pain ratings are to
be considered as exploratory since the measures are not com-
pletely independent. Finally, the use of faces as conditional stim-
uli (CS) may have introduced a bias toward ﬁnding results
involving the amygdala, as the amygdala is involved in face per-
ception and evaluation (Todorov 2011). In linewith previous neu-
roimaging experiments that used faces in backward-masking
paradigms (Breiter et al. 1996; Whalen et al. 1998), we found
that the right amygdalawasmore activated during nonconscious
versus conscious trials, indicating that there is something about
nonconscious processing of salient stimuli that activates the
right amygdala (and not differences in face perception per se).
To prevent a possible bias from differences in face perception be-
tween different face stimuli, faces were counterbalanced across
pain levels, such that each face used as a CS for high pain for
half of the participants and as a CS for low pain for the others,
and the same faces were used in conscious and nonconscious
conditions.
In conclusion, we propose a neural mechanism that conveys
nonconscious perception of treatment cues into placebo and no-
cebo responses. Our results suggest that health-related behaviors
can be triggered by cues that are not consciously perceived, not
only for pain, but perhaps also for other medical problems with
demonstrated placebo effects, like anxiety (Petrovic et al. 2005),
asthma (Wechsler et al. 2011), and depression (Kirsch et al.
2008). It is possible that the increased understanding of how im-
plicit treatment cues are conveyed into change in clinical out-
comes can stimulate changes of clinical practice and improve
therapeutic decisions.
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